55 60 65 70 75 80 85 90 200 300 400 500 600 0 4 8 12 16 20 24 APEX KSI-101 in DME – Meaningful visual and anatomical gains were achieved with KSI-101, with additional benefits with continued dosing. KSI-101 was well-tolerated N values All KSI-101 12 12 12 11 11 11 11 11 Mean OCT CST (microns) Mean Change in BCVA and OCT CST in DME All KSI-101 dose levels combined End of Study Subjects with DME (n=12) Weeks 0 4 8 12 16 20 24 2.5 mg 5 mg 10 mg KSI-101 intravitreal injection Study Design: Ongoing, Open-label Phase 1b in treatment-naïve DME All KSI-101 (N=12) Summary of AEs in the Study eye, n (%) Subjects with ≥1 AEs 1 (8.3) Treatment-related AEs 0 Serious AEs 0 Treatment-related serious AEs 0 Severe AEs 0 AEs leading to study discontinuation 0 AEs in the Study Eye, n (%) Intraocular inflammation 0 Occlusive retinal vasculitis 0 Cataract 0 Cataract traumatic* 1 (8.3) The APEX study is ongoing. Final results may be different due to additional data collection or data cleaning. AE, Adverse event; IOP, intraocular pressure. Events are investigator reported. Adverse events are treatment-emergent events with start date ≥first study drug date and ≤last study drug date + 28 days. * Anterior traumatic cataract due to aqueous humor routine sample Safety Weeks Letters: +12.0 Dryness (CST <325) Microns: -157 Mean BCVA (letters) 12